A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review
Conclusion: The patient with nasopharyngeal carcinoma in this case developed severe COVID-19 after receiving immunotherapy. For patients treated with immune checkpoint inhibitors (ICIs) in epidemic areas, the safety of ICIs in cancer patients infected with SARS-CoV-2 should be considered.
Source: In Vivo - Category: Research Authors: ZHAI, M., ZHANG, S. Tags: Articles on Covid-19 Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Coronavirus | COVID-19 | CT Scan | Epidemics | Epidemiology | Immunotherapy | Laboratory Medicine | Nasopharyngeal Cancer | Pharyngeal Cancer | Research | Respiratory Medicine | SARS